Indications for ULORIC:

Chronic management of hyperuricemia in patients with gout.


≥18yrs: initially 40mg once daily. Obtain target serum uric acid levels <6mg/dL after 2 weeks of initiating therapy; if not <6mg/dL, may increase to 80mg once daily. Gout flare prophylaxis, with an NSAID or colchicine, upon initiation of therapy and for up to 6 months, is recommended. Severe renal impairment: max 40mg once daily.


<18yrs: not established.


Concomitant azathioprine, mercaptopurine.


Not for treating asymptomatic hyperuricemia. Cardiovascular events: monitor for signs and symptoms of MI and stroke. Measure LFTs at baseline and if liver injury is suspected; interrupt therapy if ALT>3xULN and investigate cause. Do not restart if ALT>3xULN with serum total bilirubin >2xULN without alternative etiologies; for lesser elevations, use with caution. Severe hepatic impairment. Severe renal impairment (see Adult) or ESRD on dialysis. Secondary hyperuricemia (eg, Lesch-Nyhan syndrome, malignant disease, or in organ transplant recipients): not recommended. Discontinue if serious skin reactions are suspected (eg, DRESS, TEN). Pregnancy. Nursing mothers.

Pharmacologic Class:

Xanthine oxidase inhibitor.


See Contraindications. Potentiates xanthine oxidase substrate drugs (eg, theophylline).

Adverse Reactions:

Abnormal LFTs, nausea, arthralgia, rash; gout flares, hepatic failure.

How Supplied:

Tabs 40mg—30, 90, 500; 80mg—30, 100, 1000

Pricing for ULORIC

40mg tablet (Qty: 30)
Appx. price $338